Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of Moderate Buy from Brokerages

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price […]

Related Keywords

Canada ,United States ,Terry Ann Burrell ,Giuseppe Ciaramella ,Sanfordc Bernstein ,William Blair ,Us Bancorp ,Metlife Investment Management ,Wells Fargo Company ,Beam Therapeutics Inc ,Royal Bank ,Hightower Advisors ,Barclays ,Raymond James Associates ,Beam Therapeutics Company Profile ,Nasdaq ,Envestnet Asset Management Inc ,Beam Therapeutics ,Get Rating ,Marketbeat Ratings ,Ann Burrell ,Asset Management ,Tower Advisors ,Life Investment Management ,Therapeutics Inc ,Glycogen Storage Disease Type ,Beam Therapeutics Daily ,Nasdaq Beam ,Beam ,Medical ,Ratings ,Consensus ,